Revolutionizing plasma cell disorder diagnostics with mass spectrometry
30 Sept 2024
Angela Dispenzieri, MD, Professor of Medicine, Division of Hematology, Department of Internal Medicine, Mayo Clinic, discusses the use of mass spectrometry for plasma cell disorder diagnostics. Mass spectrometry of monoclonal proteins is transforming plasma cell disorder diagnostics by enhancing sensitivity and specificity beyond traditional immunofixation. This innovative approach provides detailed fingerprinting of myeloma and amyloid proteins, crucial in the era of therapeutic monoclonal antibodies. With the ability to accurately identify and monitor proteins, mass spectrometry offers revolutionary potential in diagnosing and managing plasma cell disorders, promising more precise treatment outcomes for patients.
About the company
Binding Site
Binding Site, part of Thermo Fisher Scientific, is committed to improving patient lives worldwide through education, collaboration and innovation
Binding Site provide diagnostic solutions that help doctors, clinicians and laboratory researchers across the globe diagnose and monitor blood cancers and immune system disorders.
Founded by researchers at the University of Birmingham, Binding Site has continued to build on its strong scientific foundations, supporting research and development within our field and responding to the changing needs of patients, researchers and clinicians for over 30 years.
We are committed to working in collaboration with our partners and customers to lead the way in specialised medical diagnostics, ensuring we continue to make a difference together.
